Practical Steps for Implementing Targeted Therapy in Your Clinic

Recent Trends

Over the past several years, targeted therapy has shifted from a research-focused intervention to a standard component in oncology, rheumatology, and dermatology practices. Clinics now face pressure to adopt these treatments, driven by advances in biomarker testing and the availability of oral biologics. A growing number of specialty pharmacies and diagnostic laboratories offer streamlined ordering processes, reducing the logistical burden on small to mid-size clinics. At the same time, payers are updating their coverage criteria, often requiring documentation of genetic or protein-expression testing before authorizing therapy.

• Increased use of companion diagnostics to identify eligible patients.
• Expansion of targeted agents beyond cancer to autoimmune and rare diseases.
• Rise of telemedicine for genetic counseling and follow-up monitoring.

Background

Targeted therapy works by interfering with specific molecular pathways that drive disease, rather than broadly attacking all rapidly dividing cells. Implementation in a clinic setting requires careful planning around patient selection, drug procurement, and adverse-effect management. Early adopters often faced high costs and complex reimbursement pathways. Today, more standardized protocols exist, but clinics must still navigate differences between on-label use, off-label use in clinical trials, and biomarker-driven treatment guidelines from professional societies.

“The transition from empiric to precision-based prescribing demands workflow changes that affect front-office staff, lab coordinators, and prescribing clinicians alike.”

User Concerns

Clinicians and administrators report several recurring challenges when introducing targeted therapy:

• Cost and prior authorization: Many targeted drugs fall under specialty tiers; prior authorization can delay treatment by days or weeks.
• Staff training: Nurses and pharmacists need to recognize drug-specific toxicities (e.g., rash, diarrhea, infusion reactions) and know how to manage them.
• Patient eligibility verification: Ensuring that test results match the drug’s target and that the patient has no contraindications (e.g., concurrent immunosuppression).
• Supply chain and storage: Some targeted therapies require cold chain or have short shelf lives; clinics need reliable distributor relationships.

Likely Impact

When implemented methodically, targeted therapy can improve outcomes by matching patients to treatments most likely to work. Clinics that establish clear step-by-step protocols often see fewer delays, lower financial penalties from denials, and stronger patient trust. Conversely, rushed adoption without proper workflow redesign may increase administrative burden and lead to underutilization due to staff fatigue. Over the next year, as more biosimilars and generics enter the market, cost barriers may ease, but the need for accurate diagnostic workflows will remain critical.

Data from early-implementing clinics suggest that dedicating a “precision medicine coordinator” (e.g., a nurse navigator or pharmacy specialist) reduces errors in ordering and improves compliance with monitoring schedules. The operational impact includes reallocation of staff time, investment in electronic health record tools for test-result flagging, and more frequent formulary reviews.

What to Watch Next

Several developments could alter how clinics approach targeted therapy:

• Liquid biopsy adoption: If blood-based genomic testing becomes the standard, clinics may need to update their sample collection and handling protocols.
• Value-based payment models: Payers may link reimbursement to outcomes or adherence, incentivizing clinic investment in patient support programs.
• Repurposed approvals: Existing targeted agents may receive expanded indications, requiring clinics to re-evaluate their patient panels.
• AI decision support: Algorithms that match tumor profiles to approved therapies are being integrated into EHRs; early pilots show reduced time to treatment initiation.

Clinics should monitor changes in National Comprehensive Cancer Network (NCCN) guidelines and FDA label updates quarterly, and consider forming small peer groups or subscribing to a clinical intelligence service to stay current without overwhelming staff.